Perrigo Company plc (PRGO) is a publicly traded company in the Healthcare — Drug Manufacturers - Specialty & Generic industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Is Perrigo Company plc stock overvalued or undervalued in 2026?
As of October 28, 2026, Perrigo Company plc (PRGO) trades at $15.92 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Perrigo Company plc
Market cap $2B · 52 weeks $9 – $22 (19 % below the high) · P/E no earnings · 2027 expected P/E 6.7× · Dividend 7.3 % · 10 years rising · Next earnings November 4, 2026 · expected EPS $0.51 · Closing price, Oct 28 · accounts published Aug 5.
- Valuation: P/Sales 0.6× (no earnings).
- Business: ROIC 3 % (weak).
- Balance sheet: Net cash/EBITDA 4.3× (solid).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in pharma: 1 of 4 pass
- R&D / Revenue 2.2 %, fails.
- Gross margin 35.1 %, fails.
- ROIC 3.3 %, fails.
- Net debt / EBITDA −4.3×, passes.
Against its peers (reference peers) — Perrigo Company plc: P/E —; EV/EBITDA —; ROIC 3.3 %; $2.2B. HUTCHMED (China) Limited (P/E 140×; EV/EBITDA —; ROIC -2.1 %; $2.5B), Bausch Health Companies Inc. (P/E —; EV/EBITDA 10.4×; ROIC 13.1 %; $2.6B), Surgery Partners, Inc. (P/E —; EV/EBITDA 7.2×; ROIC 4.4 %; $3.0B).
Dividend
solid · Yield 7.3 % ($1.15 per ADS in 2025) · Years raising it 10 · 5-year growth +5 % a year · Free cash flow coverage 1.5× · With $1,000 invested today you'd collect $72.90 a year ($6.08 a month).
Profitability
| Return on Equity | -55.97% |
| Return on Invested Capital | 3.27% |
| Return on Assets | -22.80% |
| Gross Margin | 33.26% |
| Operating Margin | 5.19% |
| Net Margin | -41.85% |
Financial Health
| Debt / Equity | 1.31 |
| Current Ratio | 2.32 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 0.49 |
Price Performance
| 1 month | +6.13% |
| 3 months | +57.47% |
| Year-to-date | +14.37% |
| 1 year | -25.19% |
| 3 years | -41.28% |
| 5 years | -64.74% |
| 10 years | -80.86% |
Dividend History
Paid in the last 12 months: $1.1600 per share in 4 payments.
| Date | Amount |
|---|---|
| 2026-08-28 | $0.2900 |
| 2026-05-29 | $0.2900 |
| 2026-03-02 | $0.2900 |
| 2025-11-28 | $0.2900 |
| 2025-08-29 | $0.2900 |
| 2025-05-30 | $0.2900 |
| 2025-03-07 | $0.2900 |
| 2024-11-29 | $0.2760 |
| 2024-08-30 | $0.2760 |
| 2024-05-31 | $0.2760 |
Amounts adjusted for stock splits.
Related companies: SRRK · LIVN · TARS · SUPN · HCM · HTFL · SGRY
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of PRGO: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks